Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Extramammary Paget's disease (EMPD) is a neoplastic condition primarily in the anogenital region. A subset of cases exhibits HER2 expression, generally associated with poor prognosis. This paper aimed to systematically explore the potential correlation between HER2 expression, clinicopathological features and prognosis in EMPD.
Methods: A systematic search (1990-2023) was conducted via BVS, Embase, Google Scholar, PubMed, Scopus and Web of Science. A meta-analysis with odds ratios (ORs) and confidence intervals (CIs) was performed.
Results: A total of 954 patients from 16 studies were included. The median age at diagnosis was 70.3 years, with the majority being men (71.8%). The penoscrotal area was the most common site of presentation. HER2 positivity was 25.6%, and the HER2-low proportion was 38.5%. Positive HER2 expression was correlated with EMPD dermal invasion (OR = 4.01, 95% CI: 2.11-7.62) and the presence of lymph node metastasis (OR = 3.84, 95% CI: 1.59-9.30), but not with the presence of secondary malignancies or the female gender. Gene expression among patients with IHC 2+ and 3+ was correlated with tumour dermal invasion (pooled OR = 6.43, 95% CI: 1.23-33.57). No correlation was found between HER2-low expression and dermal invasion, lymph node metastasis or the presence of secondary primary malignancies.
Conclusion: HER2 was expressed in a significant proportion in EMPD with significant correlations, suggesting its potential role as a prognostic biomarker.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajd.14490 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HER3 upregulation reduces DS-8201 sensitivity in HER2-positive tumor cells by ATR/CHK1/FoxO1 signaling cascade.
Acta Pharmacol Sin
September 2025
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
The anti-HER2 antibody‒drug conjugate (ADC) DS-8201 presents new hope for patients with advanced HER2-positive tumors. Its clinical application, however, is hindered by serious adverse reactions and reduced efficacy following long-term treatment. In this study, we investigated the factors influencing the sensitivity of DS-8201 and developed effective combination regimens to optimize its therapeutic efficacy.
View Article and Find Full Text PDFCollagen proteins, thrombospondin 1 and lumican are differentially expressed across breast cancer subtypes by functional proteomics from core needle biopsy samples of Taiwanese breast cancer.
Biochem Biophys Rep
December 2025
Division of Breast Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, 112, Taiwan.
Purpose: This study aimed to conduct functional proteomics across breast cancer subtypes with bioinformatics analyses.
Methods: Candidate proteins were identified using nanoscale liquid chromatography with tandem mass spectrometry (NanoLC-MS/MS) from core needle biopsy samples of early stage (0-III) breast cancers, followed by external validation with public domain gene-expression datasets (TCGA TARGET GTEx and TCGA BRCA).
Results: Seventeen proteins demonstrated significantly differential expression and protein-protein interaction (PPI) found the strong networks including COL2A1, COL11A1, COL6A1, COL6A2, THBS1 and LUM.
Applicability of Oncotype DX Testing in a Diverse Breast Cancer Population in Hawaii.
Breast J
September 2025
University of Hawai'i Cancer Center, Honolulu, Hawaii, USA.
The Oncotype DX test is standardly used for patients with early-stage, hormone-receptor-positive, HER2-negative breast cancers to determine the benefit from chemotherapy and the likelihood of distant recurrence. The relationship between Oncotype DX recurrence scores and race/ethnicity is still being studied. This retrospective study aims to evaluate the relationship between Oncotype DX recurrence scores, race/ethnicity, and clinicopathological factors and to support the applicability of the Oncotype DX test for a diverse breast cancer population of Hawaii.
View Article and Find Full Text PDFAntibody-bottlebrush prodrug conjugates for targeted cancer therapy.
Nat Biotechnol
September 2025
Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.
Antibody-drug conjugates (ADCs) are effective targeted therapeutics but are limited in their ability to incorporate less-potent payloads, varied drug mechanisms of action, different drug release mechanisms and tunable drug-to-antibody ratios. Here we introduce a technology to overcome these limitations called 'antibody-bottlebrush prodrug conjugates' (ABCs). An ABC consists of an IgG1 monoclonal antibody covalently conjugated to the terminus of a compact bivalent bottlebrush prodrug that has payloads bound through cleavable linkers and polyethylene glycol branches.
View Article and Find Full Text PDFA long noncoding RNA-based serum signature predicts ado-trastuzumab emtansine (T-DM1) treatment benefit in HER2+ metastatic breast cancer patients: a multicenter cohort study.
Cell Death Discov
September 2025
Department of Molecular Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Ado-trastuzumab is considered a standard treatment for patients with HER2+ metastatic breast cancer (mBC). Current clinical practices do not reliably predict therapeutic outcomes for patients who are refractory to therapy. Long noncoding RNAs (lncRNAs) are emerging as critical regulators of gene expression and therapeutic resistance, and the use of lncRNAs as tumor biomarkers is becoming more common in other diseases.
View Article and Find Full Text PDF